69 results about "Hepatitis X" patented technology

The present invention is directed to sodium hypochlorite solutions, solids, sprays, gels, powders and bandages to sanitize or disinfect against the harmful effects of diseases such as HIV or hepatitis.

The invention relates to a glycyrrhizic acid derivative, preparation thereof and use thereof. The derivative has high water solubility and high storage stability and is suitable to be used in medicaments and health-care products for treating or preventing hepatitis, liver cirrhosis, hemorrhagic fever of liver damage and liver dysfunction syndrome, allergic purpura, psoriasis vulgaris, eczematousdermatitis and the like.

The invention relates to the technical field of medicament, providing a novel application of coumarin compound imperatorin in preparing a medicament for preventing and treating virus hepatitis and resisting immunological liver injury or chemical liver injury. Pharmacological tests prove that the imperatorin has stronger activity of inhibiting hepatitis B surface antigen (HbsAg) and hepatitis B virus e antigen (HbeAg) and resisting the immunological liver injury or the chemical liver injury, so the imperatorin can be used for preparing the medicament for preventing and treating the virus hepatitis and resisting the immunological liver injury or the chemical liver injury. The imperatorin has the advantages of convenient preparation, wide sources, low price and high safety. The invention provides the novel application of the imperatorin, and provides a new medicinal source for preventing and treating the virus hepatitis and resisting the immunological liver injury or the chemical liver injury.

The invention discloses a medicament for treating fatty liver, prostatitis, nephralgia, nephritis, hypertension and diabetes. The medicament is prepared by jointly pickling poultry eggs (chicken eggs or duck eggs) by using eighteen traditional Chinese medicinal components such as inonotuso bliquus(Fr) pilat, huidouba, rhodiola rosea, momordica cochinchinensis seed, polygonum multiflorum, scindapsus aureus, lucid ganoderma, lethariella cladonioides, tall gastrodia fruit, rhodobryum giganteum par, thamnolia vermicularia and gymnadenia conopsea and edible salts, or mixing the pickled poultry eggs with medicinal juice. The medicament can be used for effectively treating the prostatitis, the diabetes, the nephralgia and the nephritis, also has a good effect for treating fatty liver and hepatitis patients and realizes efficacy of protecting liver and kidney.

The invention relates to the field of polypeptide medicament, and particularly relates to an anti-hepatitis B virus X protein peptide and polypeptide coding the peptide, and application thereof. Specifically, the invention relates to a polypeptide with functional activity to inhibit hepatitis B virus X protein (HBx) at the molecular level, cellular level and animal level, and therefore can inhibit hepatitis caused by hepatitis B virus infection of, cirrhosis caused by repeated attack of hepatitis, and the liver cancer occurred on the basis of cirrhosis. The polypeptide and peptide analogs thereof including their functional fragments and functional variants, and the genes encoding these peptides, peptide analogs or their functional fragments and functional variants can be widely used for the prevention and control of hepatopathy after hepatitis B infection including hepatitis, cirrhosis and liver cancer.

The present invention relates to in vitro methods of determining a susceptibility to non-response to a hepatitis C treatment or a susceptibility to spontaneous hepatitis C clearance in a subject infected with hepatitis C.

The invention relates to a Chinese herbal medicine, in particular to a medicine for treating hepatitis, which solves the problems of bad hepatitis treating efficacy, low cure rate and others in the prior art. The medicine for treating hepatitis comprises the following active pharmaceutical ingredients: bupleurum, root of herbaceous peony, capillary artemisia, dyers woad root, gardenia, Chinese rhubarb, umbellate pore fungus, astragalus root, pilose asiabell root, bighead atractylodes rhizome, tangerine peel, medicated leaven, germinated barley, red sange root, phellodendron bark, root of baikal skullcap, rhizoma corydalis, madder root and notoginseng. As shown by clinic applications, the medicine has the advantages that the serological biochemical criterions, for example aminopherase, bilirubin and other factors, return to normal; clinic symptoms are improved or eliminated obviously, the removal of virus indicates that the surface antigen in serum turns to negative; the HBV-DNA inspection for liver texture shows negative, the liver functions get right substantially, the effective rate is above 90% and all indicators of human body turn to normal level.

Methods of reducing hepatitis delta virus (HDV) viral loads in a patient are provided. In some embodiments, the method comprises treating the patient with lonafarnib-ritonavir co-therapy. In some embodiments, the method further comprises treating the patient with an interferon.

The invention discloses soluble micromolecular beta-1,3-glucan for improving the immunity of a hepatitis patient. The purity of the obtained target product the soluble micromolecular beta-1,3-glucan is above 95% through treatment of a series of physical methods. The target product the soluble micromolecular beta-1,3-glucan is completely water soluble, the physiological activity, especially the biology immune activity, anti-inflammatory activity and the antitumor activity have a very significant effect, and especially the soluble micromolecular beta-1,3-glucan is used for auxiliary treatment of the hepatitis patient and can improve the immunity of the hepatitis patient.

The invention relates to the technical field of medicine and the application of diterpene compounds, including glaucocalyxin B, glaucocalyxin C, glaucocalyxin D, glaucocalyxin E and glaucocalyxin F in rabdosia japonica, to preparation of anti-hepatitis virus medicines. The invention performs anti-hepatitis B surface antigen and hepatitis B core antigen experiments of diterpene compounds including glaucocalyxin B, glaucocalyxin C, glaucocalyxin D, glaucocalyxin E and glaucocalyxin F by a hepatitis B surface antigen (HBsAg) diagnostic kit and a hepatitis B core antigen (HBeAg) diagnostic kit. The result shows that these compounds have obvious anti-hepatitis B virus activity, thus, these compound can be used for preparation of anti-hepatitis B virus medicines.

The invention provides an extract which is extracted from geraniaceae plants, an extraction method of the extract, an application of the extract in the prepration of anti-helicobacter pylori infection drugs and the drugs for the treatment or prevention of gastrointestinal diseases which are caused by helicobacter pylori infection, and an application of the composition in the preparation of drugs for the treatment of hepatitis.

The invention discloses a medicament for treating hepatitis, used for restoring damaged hepatic cells to reach the purpose of treating the hepatitis. The medicament has dosage forms of decoctions, medicinal granules, pills, medicinal extracts and powders and comprises the following raw materials in proportion: 15-20g of atractylodes, 20-25g of artemisia capillaries, 15-20g of dried green orange peel, 10-20g of polyporus, 10-15g of ricepaper pith and 10-15g of glycyrrhiza.

The invention discloses medicine for regulating liver regeneration and a preparation method of the medicine. The medicine is prepared by the following active ingredients in parts by weight: 1-5 parts of rehmannia glutinosa, 2-8 parts of herba artemisiae scopariae, 2-6 parts of turmeric, 1-3 parts of radix glycyrrhizae and 1-5 parts of Chinese magnoliavine. Long term clinical application of the medicine proves that the medicine has a positive curative effect on preventing and treating posthepatitic cirrhosis and liver cancer, and is mainly suitable for an active stage and a progressive stage of chronic hepatitis, an experiment proves that the medicine has synergistic functions of regulation of the liver regeneration, antivirus, anti-liver injury, anti-liver fibrosis and prevention and treatment of the liver cancer, the medicine is mainly available to people with high risks of the hepatocirrhosis and the liver cancer caused by the chronic hepatitis and people with the early liver cancer or after liver cancer operations (mainly virus replication, inflammation, liver injury and liver fibrosis); and the medicine has an evidence-based clinical medical evidence at a higher level.

The invention relates to application of LTA4H as a biomarker for indicating an intrahepatic nodule and pre-warning liver cancer at an early stage, in particular to application of the following reagents in preparing a kit for diagnosing the intrahepatic nodule of an object or diagnosing whether the object is in a vicious transformation critical phase from hepatitis to liver cancer, and the reagents comprise: (1) a reagent which is specifically combined with LAT4H; (2) a reagent which is specifically combined with PLA2G6; and (3) a reagent which is randomly selected and specifically combined with EPS8L2. The key critical stage of transformation from hepatitis to liver cancer is found based on an analysis on time sequence dynamics and network correlation, so that a novel direction is provided for being clinically applied to early-stage liver cancer treatment of a patient with hepatitis, judging whether the patient is in the critical stage of vicious transformation from hepatitis to liver cancer, and preventing deterioration of hepatitis and liver cancer.

The present invention relates to methods of treatment of hepatitis C using prasugrel. The methods of the present invention can be used in patients with hepatitis C administering prasugrel in combination with one or more anti-hepatitis C drugs.

A combined vaccine for treating hepatitis a, hepatitis b and hepatitis e is characterized in comprising deactivated hepatitis a virus 200-1000 U/mL, recombined hepatitis b virus surface antigen 10-40 mu g/mL, and recombined hepatitis e virus antigen 10-50 mu g/mL.The inventive combined vaccine uses deactivated HAV and recombined HBsAg with good safety and immunogenicigy. Former research has provn that the recombined HEV protein also has good safety and immunogenicigy; and can be used for development of hepatitis e vaccine. The inventive combined vaccine is technologically feasible. The invention can greatly reduce production costs of viral hepatitis vaccine and market price, and improve coverage ratio of vaccine due to the advantages of convenience, multiple effect and low cost.

The invention relates to a traditional Chinese medicine for treating cholestatic hepatitis. The traditional Chinese medicine for treating the cholestatic hepatitis is prepared from the following medicinal materials in parts by weight: 14 parts of piper cubeba, 12 parts of elsholtzia, 8 parts of Himalayan horsegentian herb, 10 parts of melilot, 14 parts of pleione saxicola, 14 parts of lacebark pine cone, 16 parts of bodinier caper, 8 parts of altingia chingii metc., 14 parts of auricled hedyotis herb, 13 parts of cantonese speranskia, 16 parts of tamarindus, 15 parts of coriaria sinica, 12 parts of buddleja asiatica, 14 parts of combretum leaf, 8 parts of hemiboea subcapitata, 10 parts of codonopsis convolvulacea and 12 parts of lowdaphne stringbush flower and leaf. A clinical experiment proves that the traditional Chinese medicine for treating the cholestatic hepatitis can be used for safely and effectively treating the cholestatic hepatitis.

A traditional Chinese medicine composition for curing HBV, hepatitis B, cirrhosis ascites and jaundice hepatitis comprises, by weight, 35-45 parts of Indian damnacanthus herb, 25-35 parts of rush, 15-25 parts of plantain herb, 25-35 parts of aeschynomene herb, 15-25 parts of honeysuckle, 15-25 parts of bittersweet herb, 35-45 parts of snow of June herb, 8-12 parts of gamdir vine, 35-45 parts of China starjasmine, 4-6 parts of root of hempleaf negundo chastetree, 4-6 parts of tendril-leaved fritillary bulb, 15-25 parts of mohonia fortunei, 25-35 parts of yam, 8-12 parts of rhizome imperatae and 12-17 parts of perfoliate knotweed herb. The traditional Chinese medicine composition has the advantages of being capable of curing acute and chronic jaundice hepatitis A virus and B virus and the HBV effectively, quick to take effect, free of toxic and side effects, simple in preparation and prone to industrial production.

A Chinese medicine for treating hepatitis B is prepared from dextrin, cane sugar and 4 Chinese-medicinal materials including giant knotweed rhizome, oldenlandia, astragalus root, etc. Its preparing process is also disclosed.

The invention discloses a healthy seasoning for the patients of hepatitis and hepatocirrhosis to eat which is manufactured by the materials of the following weight portions; 4 to 6 portions of villous amomum, 4 to 6 portions of angelica, 6 to portions of costus root, 8 to 12 portions of oriental blueberry leaf, 4 to 6 portions of wrinkled glanthyssop, 4 to 6 portions of rhizoma kaempfferiae, 8 to 12 portions of tremella, 8 to 12 portions of mushroom, 8 to 12 portions of dried orange peel, 10 to 15 portions of medlar and 8 to 12 portions of cassia seed. The components of the invention not only can season, but also are beneficial for the patients of hepatitis and hepatocirrhosis toimprove appetite, neutralizing middle-jiao energy, eliminating dampness, nourishing liver and kidney, improving the immunity and easing the disease to develop. The commonly used seasonings like zanthoxylum, pepper, red pepper, fennel and ginger that are not beneficial to the hepatitis and the hepatocirrhosis are removed and the seasonings like mushroom, tremella, medlar, cassia seed and poria cocos that are beneficial to the hepatitis and the hepatocirrhosis are added.

The inventor discovers that Houttuynoid A has a prevention effect on mice acute liver injury induced by D-galactosamine (D-GalN) and has a prevention effect on mice acute liver injury induced by carbon tetrachloride (CCl4) through a pharmacological study. Therefore, Houttuynoid A can be utilized to prepare the medicines for preventing and treating liver injury or hepatitis. Application of Houttuynoid A on preparation of the medicine for preventing and treating liver injury provided by the invention is disclosed firstly. The skeleton type belongs to new skeleton type, and the activity of Houttuynoid A on the treatment effect of liver injury is unexpectedly strong; and the probability that any revelation is provided by other compounds does not exist, Houttuynoid A has the excellent substantive features, and Houttuynoid A obviously has a remarkable progress when being used for preventing liver injury.

The invention aims at providing an acyclic nucleotide derivative shown as a formula I and a non-toxic pharmaceutically acceptable salt thereof, a pharmaceutical composition which contains the acyclic nucleotide derivative shown as the formula I and the non-toxic pharmaceutically acceptable salt thereof as an active ingredient and employs common pharmaceutical excipients in the pharmacy field, and application of the pharmaceutical composition to treat hepatitis and virus hepatitis B as a medicine. The formula I is shown in the specification.

The present invention is based on a finding that a hepatitis B virus antibody inhibits binding of a surface antigen (HBsAg) of hepatitis B virus to heparan sulfate proteoglycan, thereby preventing cccDNA formation of the hepatitis B virus. It is expected that utilizing the pharmaceutical composition and the method of preventing cccDNA formation of hepatitis B virus of the present invention can fundamentally treat chronic hepatitis B and also prevent a recurrence of hepatitis in a hepatitis B patient after liver transplant surgery. Further, according to the present invention, a material for preventing or treating hepatitis B can be newly identified by confirming whether cccDNA formation is inhibited or not. In addition, according to the present invention, a treatment supplement capable of being administered in combination with the hepatitis B virus antibody can be newly identified.